Search research articles
Contact Us
Filters
Showing results (251-260 of 270) with videos related to
Page
of 27
Sort By:
Plos One
|
September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity
Sarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Iscience
|
December 8, 2021
Functional organization of the maternal and paternal human 4D Nucleome
Stephen Lindsly, Wenlong Jia, Haiming Chen, et al.
Molecular Cancer Research : MCR
|
January 27, 2017
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects
Haiming Chen, Mingjie Li, Eric Sanchez, et al.
British Journal of Haematology
|
May 23, 2020
Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
Scott Jew, Tiffany Chang, Sean Bujarski, et al.
Targeted Oncology
|
December 13, 2017
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez, Emily J Smith, Moryel A Yashar, et al.
Haematologica
|
December 31, 2016
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, et al.
British Journal of Haematology
|
August 20, 2019
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression
Haiming Chen, Mingjie Li, Eric Sanchez, et al.
European Journal of Haematology
|
May 16, 2021
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
Sean Bujarski, Marissa-Skye Goldwater, Bernard Sean Regidor, et al.
British Journal of Haematology
|
December 20, 2020
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
Haiming Chen, Mingjie Li, Nicole Ng, et al.
Blood
|
March 21, 2007
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth
Haiming Chen, Melinda S Gordon, Richard A Campbell, et al.
Page
of 27
Search research articles
Search
Showing results (251-260 of 270) with videos related to
Sort By:
Page
of 27
Plos One
|
September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity
Sarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Iscience
|
December 8, 2021
Functional organization of the maternal and paternal human 4D Nucleome
Stephen Lindsly, Wenlong Jia, Haiming Chen, et al.
Molecular Cancer Research : MCR
|
January 27, 2017
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects
Haiming Chen, Mingjie Li, Eric Sanchez, et al.
British Journal of Haematology
|
May 23, 2020
Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
Scott Jew, Tiffany Chang, Sean Bujarski, et al.
Targeted Oncology
|
December 13, 2017
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Eric Sanchez, Emily J Smith, Moryel A Yashar, et al.
Haematologica
|
December 31, 2016
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, et al.
British Journal of Haematology
|
August 20, 2019
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression
Haiming Chen, Mingjie Li, Eric Sanchez, et al.
European Journal of Haematology
|
May 16, 2021
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
Sean Bujarski, Marissa-Skye Goldwater, Bernard Sean Regidor, et al.
British Journal of Haematology
|
December 20, 2020
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
Haiming Chen, Mingjie Li, Nicole Ng, et al.
Blood
|
March 21, 2007
Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth
Haiming Chen, Melinda S Gordon, Richard A Campbell, et al.
Page
of 27